Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

Recently the Company announced that more than 133 patients have been enrolled in its MAESTRO-03 trial. An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Jeffrey T. Manuel, assistant professor in Southern Illinois ... of Arts and Sciences, is teaming up with the ... fuels in Illinois. , “Farmers, researchers, business ... build Illinois’ biofuels industry for decades,” Manuel said. “This ... agricultural and business history. , “Fuel alcohol has ...
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Stronger ... healthcare, construction, finance and consumer electronics will help ... reason, industry research firm IBISWorld has added a ... its growing industry report collection. , The Biometrics ... for biometric technologies such as fingerprint, iris, retina ...
(Date:10/30/2014)... 30, 2014 The report “Fragrance Ingredients ... Application (Cosmetics & Toiletries, and Soaps & Detergents) & ... has defined and segmented the Fragrance Ingredients Market with ... terms of value. The market has been segmented on ... Europe, Asia-Pacific, Latin America, and Rest of the World ...
Breaking Biology Technology:SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5
... , , , SUNNYVALE, ... leader in the field of radiosurgery, announced today that its management is scheduled ... City on Thursday, September 10, 2009 at 11:00 a.m. ET (8:00 a.m. PT). ... available online from the investor relations page of the Company,s Web site at ...
... ... its national print advertising campaign for Cobroxin, the first clinically proven, over-the-counter treatment for ... will run in Arthritis Today, Prevention, Health, Star, Woman,s World, Soap Opera, and Self ... (Vocus) ...
... , CAMBRIDGE, Mass., Sept. 3 Idenix ... management will present a corporate overview at the upcoming Thomas ... at 10:55 a.m. ET at the Four Seasons Hotel in ... Conference on Monday, September( )14, 2009 at 3:55 p.m. ET ...
Cached Biology Technology:Accuray Incorporated to Present at Robert Baird 2009 Healthcare Conference 2Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain 2
(Date:10/29/2014)... research presented at the Society for Integrative Oncology ... for the first time that it is possible ... readily available nutritional supplement, AHCC. ... Smith, Pharm.D., associate professor in the Department of ... of Texas Health Science Center at Houston (UTHealth) ...
(Date:10/29/2014)... overwhelming number of chemicals from household and industrial products ... our bodies. But for most of them, scientists have ... they,ve taken the first step toward doing that by ... Their new method is published in the ACS journal ... Wambaugh and colleagues note that the risks to human ...
(Date:10/29/2014)... in German . ... and Peter Schlögelhofer at the Max F. Perutz Laboratories ... University of Vienna dived into the process of meiosis ... display an inversion of the standard meiotic phases. The ... Nature Communications . , Meiosis is the two-step ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Meiotic cell division 'the other way round' 2
... Molecular Imaging Labs (MI Labs) have succeeded in combining ... of equipment. These techniques are particularly useful for cancer ... microSPECT. SPECT and PET can be performed simultaneously and ... microPET. The new device is known as the VECTor ...
... Properties SA announces the winners of the Reaxys PhD ... PhD or having completed a PhD within the last ... the fields of organic, organometallic and inorganic chemistry. ... launched in January 2010. Submissions consisted of a representative ...
... Navarra, the Polytechnic University of Madrid (CBGP), the University ... Institute of Agricultural Research have managed to sequence the ... olive tree. The study, included in the June issue ... of the genome of a pathogenic bacteria undertaken in ...
Cached Biology News:TU Delft and MI Labs merge PET and SPECT biomedical imaging techniques and increase resolution 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 3Genome of bacteria responsible for tuberculosis of olive tree sequenced 2
...
Fetal Calf Serum Replacement (Bistec) serum...
NEWBORN CALF SERUM AND PLASMA...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Biology Products: